Esther S Trueblood

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 3

Top Topics

Tandem Mass Spectrometry

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Ryan A Heiser, Anthony T Cao, Weiping Zeng, Michelle Ulrich, Patrick Younan, Martha E Anderson, Esther S Trueblood, Mechthild Jonas, Robert Thurman, Che-Leung Law, Shyra J Gardai
Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity. Molecular cancer therapeutics (2023)
Robert P Lyon, Mechthild Jonas, Christopher Frantz, Esther S Trueblood, Roma Yumul, Lori Westendorf, Christopher J Hale, Jackie L Stilwell, Narayana Yeddula, Katie M Snead, Vineet Kumar, Gabriela I Patilea-Vrana, Kerry Klussman, Maureen C Ryan
SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications. Molecular cancer therapeutics (2023)
Ryan D Lyski, Lauren B Bou, Uland Y Lau, David W Meyer, Julia H Cochran, Nicole M Okeley, Kim K Emmerton, Francisco Zapata, Jessica K Simmons, Esther S Trueblood, David J Ortiz, Margo C Zaval, Katie M Snead, Steven Jin, Lauren M Farr, Maureen C Ryan, Peter D Senter, Scott C Jeffrey
Development of Novel Antibody-Camptothecin Conjugates. Molecular cancer therapeutics 20 (2) (2020)